Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access: The DELIVER study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Polad, J. | - |
dc.contributor.author | Wöhrle, J. | - |
dc.contributor.author | Singh, B. | - |
dc.contributor.author | Chag, M. | - |
dc.contributor.author | Rha, S.-W. | - |
dc.contributor.author | Malik, F.-T.-N. | - |
dc.contributor.author | van, Eck M. | - |
dc.contributor.author | Rottbauer, W. | - |
dc.date.accessioned | 2021-09-05T15:52:40Z | - |
dc.date.available | 2021-09-05T15:52:40Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1553-8389 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/100690 | - |
dc.description.abstract | Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71%): mean lesion length was 26.7 ± 17.5. mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications. © 2014 Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Inc. | - |
dc.subject | zotarolimus | - |
dc.subject | cardiovascular agent | - |
dc.subject | rapamycin | - |
dc.subject | zotarolimus | - |
dc.subject | adult | - |
dc.subject | article | - |
dc.subject | controlled study | - |
dc.subject | coronary artery disease | - |
dc.subject | disease severity | - |
dc.subject | drug eluting coronary stent | - |
dc.subject | female | - |
dc.subject | femoral access | - |
dc.subject | guiding catheter | - |
dc.subject | heart disease | - |
dc.subject | human | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | medical device complication | - |
dc.subject | multicenter study | - |
dc.subject | percutaneous coronary intervention | - |
dc.subject | post hoc analysis | - |
dc.subject | priority journal | - |
dc.subject | prospective study | - |
dc.subject | radial access | - |
dc.subject | stent thrombosis | - |
dc.subject | target lesion failure | - |
dc.subject | treatment outcome | - |
dc.subject | vascular access | - |
dc.subject | aged | - |
dc.subject | analogs and derivatives | - |
dc.subject | clinical trial | - |
dc.subject | comparative study | - |
dc.subject | drug eluting stent | - |
dc.subject | middle aged | - |
dc.subject | Myocardial Infarction | - |
dc.subject | procedures | - |
dc.subject | risk factor | - |
dc.subject | very elderly | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Aged, 80 and over | - |
dc.subject | Cardiovascular Agents | - |
dc.subject | Coronary Artery Disease | - |
dc.subject | Drug-Eluting Stents | - |
dc.subject | Female | - |
dc.subject | Humans | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Myocardial Infarction | - |
dc.subject | Percutaneous Coronary Intervention | - |
dc.subject | Prospective Studies | - |
dc.subject | Risk Factors | - |
dc.subject | Sirolimus | - |
dc.subject | Treatment Outcome | - |
dc.title | Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access: The DELIVER study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, S.-W. | - |
dc.identifier.doi | 10.1016/j.carrev.2014.07.002 | - |
dc.identifier.scopusid | 2-s2.0-84907308460 | - |
dc.identifier.bibliographicCitation | Cardiovascular Revascularization Medicine, v.15, no.5, pp.289 - 294 | - |
dc.relation.isPartOf | Cardiovascular Revascularization Medicine | - |
dc.citation.title | Cardiovascular Revascularization Medicine | - |
dc.citation.volume | 15 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 289 | - |
dc.citation.endPage | 294 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | zotarolimus | - |
dc.subject.keywordPlus | cardiovascular agent | - |
dc.subject.keywordPlus | rapamycin | - |
dc.subject.keywordPlus | zotarolimus | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | coronary artery disease | - |
dc.subject.keywordPlus | disease severity | - |
dc.subject.keywordPlus | drug eluting coronary stent | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | femoral access | - |
dc.subject.keywordPlus | guiding catheter | - |
dc.subject.keywordPlus | heart disease | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | medical device complication | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | percutaneous coronary intervention | - |
dc.subject.keywordPlus | post hoc analysis | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | radial access | - |
dc.subject.keywordPlus | stent thrombosis | - |
dc.subject.keywordPlus | target lesion failure | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | vascular access | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | analogs and derivatives | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | drug eluting stent | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | Myocardial Infarction | - |
dc.subject.keywordPlus | procedures | - |
dc.subject.keywordPlus | risk factor | - |
dc.subject.keywordPlus | very elderly | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Aged, 80 and over | - |
dc.subject.keywordPlus | Cardiovascular Agents | - |
dc.subject.keywordPlus | Coronary Artery Disease | - |
dc.subject.keywordPlus | Drug-Eluting Stents | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Myocardial Infarction | - |
dc.subject.keywordPlus | Percutaneous Coronary Intervention | - |
dc.subject.keywordPlus | Prospective Studies | - |
dc.subject.keywordPlus | Risk Factors | - |
dc.subject.keywordPlus | Sirolimus | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordAuthor | Deliverability | - |
dc.subject.keywordAuthor | Radial access | - |
dc.subject.keywordAuthor | Resolute integrity | - |
dc.subject.keywordAuthor | Zotarolimus-eluting stent | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.